Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers by Shaogui Wan et al.
Wan et al. BMC Cancer 2013, 13:340
http://www.biomedcentral.com/1471-2407/13/340RESEARCH ARTICLE Open AccessPost-diagnosis hemoglobin change associates with
overall survival of multiple malignancies – results
from a 14-year hospital-based cohort of lung,
breast, colorectal, and liver cancers
Shaogui Wan1, Yinzhi Lai1, Ronald E Myers1, Bingshan Li3, Juan P Palazzo2, Ashlie L Burkart2, Guokai Chen4,
Jinliang Xing5 and Hushan Yang1*Abstract
Background: Anemia refers to low hemoglobin (Hb) level and is a risk factor of cancer patient survival. The National
Comprehensive Cancer Network recently suggested that post-diagnosis Hb change, regardless of baseline Hb level,
indicates the potential presence of anemia. However, there is no epidemiological study evaluating whether Hb change
has direct prognostic values for cancer patients at the population level.
Methods: We identified 6675 patients with a diagnosis of primary lung, breast, colorectal, or liver cancer who visited
the Kimmel Cancer Center at the Thomas Jefferson University from 1998 to 2011. All patients had at least two Hb
measurements within the first six months after diagnosis. We analyzed the main, dose-dependent, and time-dependent
effects of Hb changes on patient survival.
Results: Compared to patients with a low Hb change (|ΔHb|≤2.6), those having a |ΔHb|>2.6 exhibited a significantly
shorter survival (hazard ratio=1.40, 95% confidence interval 1.31-1.50, P=4.5 × 10-22, Plog rank=1.6 × 10
-39). This association
remained significant across the four cancer types. Bootstrap resampling validated these findings 100% of the time with
P<0.01 in all patients and in patients of individual cancers. The association exhibited an apparent U-shape dose-
dependent pattern. Time-dependent modeling demonstrated that the effect of Hb change on the survival of the
overall patient population persisted for approximately 4.5 years after diagnosis.
Conclusion: Post-diagnosis Hb change associates with the survival of multiple cancers and may have clinical values in
tailoring anti-anemia treatments. Because Hb level is frequently measured during cancer treatment, Hb changes may
be a potentially important variable in building cancer prognosis models.
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Anemia is a condition that develops when whole blood
lacks sufficient healthy red blood cells or hemoglobin
(Hb), an oxygen-carrying protein within red blood cells.
Cancer-associated anemia is one of the most common
paraneoplastic syndromes during cancer progression or
treatment and is prevalent in 30% to 90% of cancer pa-
tients [1]. Although anemia incidence varies with cancer* Correspondence: hushan.yang@jefferson.edu
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reproduction in any medium, provided the ortypes, stages and patient characteristics, it has been esti-
mated that over 40% of all cancer patients are anemic
at diagnosis, a rate that increases by an additional 40%
after chemotherapy or radiation therapy treatments
[1-4]. Because cancer-associated anemia has been docu-
mented as an adverse prognostic factor as well as pre-
dictor of treatment response, [5,6] evaluations of anemia
and anti-anemia treatments have significant clinical
implications.
The diagnosis and treatment of anemia are influenced
by various factors, such as hemorrhage, hemolysis, nutri-
tional deficiency, hereditary disease, renal dysfunction,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Since clinical symptoms of anemia start slowly, Hb level
is currently the most important predictor in guiding
anemia evaluation and treatment, regardless of the under-
lying causes [3]. Correction of cancer-associated anemia is
usually achieved by blood transfusion with packed red
blood cells (PRBCs) or erythropoiesis-stimulating agents
(ESAs). However, considerable controversy regarding the
safety and restrictions on the correction modality of
cancer-associated anemia has been recently reported. For
instance, several recent meta-analysis studies reported that
ESA administrations, while reducing the incidence of clin-
ically defined anemia, may confer an adverse survival to
patients exhibiting a large change in Hb levels during
treatment [9-12]. In comparison, other studies did not
identify such significant effects of ESA use on patient
mortality [13,14]. These studies suggested the complexity
in the diagnosis and tailored treatment of anemia in the
context of broad variations in Hb levels.
Given the wide variations in Hb level among cancer
patients and even healthy individuals, it is impractical to
define a clinically universal “normal” Hb value. More-
over, during anti-anemia treatment in clinics, it remains
controversial as to the time to start initial treatment and
the targeted range of Hb levels. For example, the base-
line Hb values that trigger ESA treatment for patients
with cancer- or therapy-induced anemia range from 8 to
11 g/dL under different practice guidelines [3,15-18].
The newly updated National Comprehensive Cancer
Network (NCCN) guideline suggests that in non-anemic
patients with a high baseline Hb level, a drop of 2 g/dL
or more should be evaluated for the presence of anemia
[3]. This raises the question whether a change in Hb
levels during follow-up or treatment, regardless of base-
line or single time point Hb levels, can directly predict
patient prognosis. In the present study, we sought to
utilize a large hospital-based cancer patient cohort to
comprehensively evaluate post-diagnosis Hb change
(ΔHb) as a predictor of overall survival in patients with
lung, breast, colorectal, or liver cancer, four of the most
common causes of cancer-related deaths. To the best of
our knowledge, this is the first population-based epi-
demiological study that evaluates Hb changes (either an




Subjects in this study were identified from a hospital-
based cohort of patients with histologically confirmed
primary lung, breast, colorectal, or liver cancer, who vis-
ited the Kimmel Cancer Center at Thomas Jefferson
University with an initial diagnosis date from 1998 to
2011. For this analysis, a total of 6675 patients wereincluded who had at least two Hb measurements within
the first six months after primary cancer diagnosis. This
study was approved by the Institutional Review Board of
Thomas Jefferson University.
Data collection
Demographic and clinical data were obtained from med-
ical chart review. Demographic variables included age,
gender, and ethnicity. Clinical variables included tumor
stage, tumor grade and treatments including surgery,
chemotherapy and radiation therapy. The routine clin-
ical laboratory tests of complete blood count panel, in-
cluding Hb values and dates of measurement, were
obtained from systemic review of electronic medical
charts. The maximum and minimum values of Hb levels
within six months after cancer diagnosis were used to
calculate Hb change (ΔHb), and the date of Hb measure-
ments were used to determine the plus or minus sign of
ΔHb. When the minimum value was measured before
the maximum value, the sign of ΔHb was plus, indicat-
ing an increase in Hb level. Otherwise, the sign of ΔHb
was minus, indicating a decrease in Hb level.
Statistical analysis
The clinical endpoint analyzed in this study was overall
survival of cancer patients. Overall survival time was de-
fined as the time from initial cancer diagnosis to death
from any cause or last follow-up. Patients who were alive
at last follow-up were censored for analysis. The associa-
tions between ΔHb and overall survival were estimated
using hazard ratio (HR) and 95% confidence interval
(95% CI) calculated by multivariate Cox proportional
hazards model, adjusting for age, gender, ethnicity,
tumor stage, tumor grade, surgery, chemotherapy, and
radiation therapy, where appropriate. The results of the
main effects analyses were internally validated using the
bootstrap resampling method [19]. A total of 100 boot-
strap samples were generated for each analysis. Each
time, a bootstrap sample was drawn from the original
dataset and the P value for the analysis was calculated.
The number of times with a P value < 0.01 was counted.
Dose-dependent analyses were conducted, assuming
ΔHb as both a categorical and a continuous variable, by
multivariate Cox proportional hazards model and frac-
tional polynomial regression model, respectively, ad-
justing for age, gender, ethnicity, tumor stage, tumor
grade, surgery, chemotherapy, and radiation therapy
[20]. The distributions of absolutely changed Hb values
between gender and cancer sites were compared by Stu-
dent’s t test. Time-dependent analyses were conducted
using flexible parametric modeling framework that ana-
lyzes the interaction between ΔHb and survival time,
and confers a time-dependent effect of ΔHb on patient
survival adjusting for other host and clinical variables
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Meier method and compared using the log rank test
with anemia indicated by a Hb level of less than 12 g/dL
[3]. Statistical analyses in this study were conducted
using SAS 9.2 (SAS Institute, Cary, NC) and STATA
12.0 (STATA Corp., College Station, TX) software pack-
ages. All P values were 2-sided. P≤0.05 was considered
statistical significant.Table 1 Characteristics of the study population
All cancers (n=6675) Lung (n=2367)
Variables No. of patients (%) No. of patients (%)









Stage 0 325(4.87) 1(0.04)
Stage 1 1764(26.43) 533(22.52)
Stage 2 1272(19.06) 158(6.68)
Stage 3 1207(18.08) 465(19.65)






















Characteristics of study population
A total of 6675 cancer patients were included in the ana-
lysis for this study, with an average age of 62.4 (± stand-
ard deviation, 11.3) years. The distributions of host
variables were summarized in Table 1. There were 2367
lung cancer patients, 1739 breast cancer patients, 1860
colorectal cancer (CRC) patients, and 709 liver cancerBreast (n=1739) CRC (n=1860) Liver (n=709)
No. of patients (%) No. of patients (%) No. of patients (%)
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13.3), 64.7 (± 13.8), and 61.0 (± 11.3), respectively. In all
cancer patients, a relatively similar distribution of patients
was observed among stages 1 to 4 (from 18.08% to
26.43%). The majority of patients had moderately (33.86%)
or poorly (22.68%) differentiated tumors. Most patients re-
ceived surgical resection (72.39%), especially those with
breast (94.54%) and colorectal cancers (88.71%). Approxi-
mately 43% of patients received chemotherapy with a rela-
tively similar distribution across the four cancer types.
About 28.9% of patients received radiation therapy. The
median follow-up time of all patients in this study was
26.8 months (quartile range, 8.8-69.4) and the median sur-
vival time of censored patients was 58.7 months (quartile
range, 26.2-100.4). Figure 1 shows the distribution of abso-
lute ΔHb (|ΔHb|) in different cancers by gender status. A
borderline significant difference between male and female
patients was noticed in lung (P=0.056) and colorectal
(P=0.096), but not liver cancer patients (P=0.850).
The |ΔHb| value in breast cancer patients was signifi-
cantly lower than that of the female patients of the other
three cancers with P<0.0001.
Post-diagnosis Hb changes and the overall survival of
cancer patients
The associations between ΔHb and patient survival were
estimated by multivariate Cox proportional hazard
model. First, we analyzed |ΔHb| and overall survival in
all cancer patients as well as in patients with individual
cancers using a median cut-off value of 2.6 g/dLFigure 1 Hb changes in different cancer types by gender. Breast, breas
lung cancer patients; CRC_F, female colorectal cancer patients; CRC_M, ma
Liver_M, male liver cancer patients. The grey boxes were quartile range of
indicated maximum and minimum changed values of Hb, respectively. Themeasured in all cancer patients. As shown in Table 2, pa-
tients with a higher level of |ΔHb| exhibited a significantly
poorer survival, compared to those with a low |ΔHb| level,
with an HR of 1.40 (95% CI 1.31-1.50, P=4.5×10-22,
Plog rank=1.6×10
-39). Similar results were found in pa-
tients with either a decreased Hb (ΔHb<−2.6) (HR=1.35,
95% CI 1.25-1.46, P=3.0×10-15) or an increased Hb
(ΔHb>2.6) (HR=1.53, 95%CI 1.39-1.69, P=5.7×10-18). The
significant association between |ΔHb| and patient sur-
vival remained prominent across the four cancer types
included in this study, with an HR (95% CI, P value, log
rank P value) of 1.32 (1.20-1.46, P=2.7×10-8, Plog rank=
8.9×10-4), 1.49 (1.19-1.86, P=4.3×10-4, Plog rank=6.5×10
-10),
1.46 (1.27-1.68, P=7.9×10-8, Plog rank=4.6×10
-8), and 1.45
(1.20-1.74, P=7.9×10-5, Plog rank=1.6×10
-2) for lung, breast,
colorectal, and liver cancer, respectively. Kaplan Meier
analysis demonstrated a significantly different overall sur-
vival time between patients with higher- and lower-than-
median |ΔHb| in all cancer patients as well as in patients
with individual cancers (data not shown). We then
conducted internal validation using bootstrap resampling
and demonstrated that the significant association between
|ΔHb| and patient survival was validated 100% of times in
all cancer patients combined, as well as in patients with
individual cancer types (Table 2). In concordance with
previous reports, anemia at baseline (baseline Hb < 12 g/L)
conferred a significant adverse effect on patient survival
(Additional file 1: Table S1). A joint analysis between base-
line Hb level and Hb change in the combined cohort and
individual cancer sites indicated the Hb changes addedt cancer patients, Lung_F, female lung cancer patients; Lung_M, male
le colorectal cancer patients; Liver_F, female liver cancer patients;
absolutely Hb changes from 25-75%, the upper and lower error bars
indicated groups were compared by Student’s t test.
Table 2 The association between Hb changes and the overall survival of cancer patients
Cancers Hb changes Dead Alive HR (95% CI)* P value Validation† Log-rank P
All cancers
By |ΔHb|
|ΔHb| ≤ 2.6 1585 1831 1.00
|ΔHb| > 2.6 1957 1302 1.40 (1.31-1.50) 4.5 x 10-22 100 1.6 x 10-39
By ΔHb
−2.6 ≤ ΔHb ≤ 2.6 1585 1831 1.00
ΔHb < −2.6 1357 975 1.35 (1.25-1.46) 3.0 x 10-15 100
ΔHb > 2.6 600 327 1.53 (1.39-1.69) 5.7 x 10-18 100 9.4 x 10-40
Lung cancer
By |ΔHb|
|ΔHb| ≤ 2.6 756 281 1.00
|ΔHb| > 2.6 1039 291 1.32 (1.20-1.46) 2.7 x 10-8 100 8.9 x 10-4
By ΔHb
−2.6 ≤ ΔHb ≤ 2.6 756 281 1.00
ΔHb < −2.6 774 246 1.25 (1.12-1.38) 3.7 x 10-5 97
ΔHb > 2.6 265 45 1.59 (1.38-1.84) 1.8 x 10-10 100 2.3 x 10-5
Breast cancer
By |ΔHb|
|ΔHb| ≤ 2.6 195 927 1.00
|ΔHb| > 2.6 170 447 1.49 (1.19-1.86) 4.3 x 10-4 100 6.5 x 10-10
By ΔHb
−2.6 ≤ ΔHb ≤ 2.6 195 927 1.00
ΔHb < −2.6 135 377 1.45 (1.14-1.84) 0.002 70
ΔHb > 2.6 35 70 1.65 (1.14-2.40) 0.008 58 1.5 x 10-9
Colorectal cancer
By |ΔHb|
|ΔHb| ≤ 2.6 360 506 1.00
|ΔHb| > 2.6 514 480 1.46 (1.27-1.68) 7.9 x 10-8 100 4.6 x 10-8
By ΔHb
−2.6 ≤ ΔHb ≤ 2.6 360 506 1.00
ΔHb < −2.6 281 299 1.46 (1.24-1.71) 3.4 x 10-6 100
ΔHb > 2.6 233 181 1.46 (1.23-1.73) 1.4 x 10-5 100 4.5 x 10-8
Liver cancer
By |ΔHb|
|ΔHb| ≤ 2.6 274 117 1.00
|ΔHb| > 2.6 234 84 1.45 (1.20-1.74) 7.9 x 10-5 100 0.016
By ΔHb
−2.6 ≤ ΔHb ≤ 2.6 274 117 1.00
ΔHb < −2.6 167 53 1.50 (1.23-1.83) 8.0 x 10-5 87
ΔHb > 2.6 67 31 1.33 (1.01-1.76) 0.044 34 0.011
*Adjusted for age, gender, ethnicity, tumor stage, tumor grade, chemotherapy, radiation therapy, and surgery. †The number of times with P<0.01 in 100
resamplings of bootstrap internal validation. |ΔHb|, the maximum absolute Hb change during the first six months after cancer diagnosis. The cut off was
determined using the median value (2.6 g/dL) of all cancer patients. ΔHb<−2.6 indicated decreased Hb changes and ΔHb>2.6 indicated increased Hb changes.
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(Additional file 1: Table S2). For instance, in the overall
cohort, compared to patients with high baseline Hb and
small Hb change, the risk of death was 1.23 (95% CI 1.09-
1.39), P=0.0008, 1.34 (95% CI 1.19-1.51), P=1.6×10-6, and
1.75 (95% CI 1.58-1.94), P=4.9×10-26) for those with a high
baseline Hb and large Hb change, low baseline Hb and
small Hb change, and low baseline Hb and large Hb
change, respectively.
Dose-dependent effects of Hb changes on cancer patient
survival
To evaluate the observed associations between ΔHb and
cancer survival in a more dynamic manner, we analyzed
the dose-dependent effects of ΔHb as both a categorical
and a continuous variable, using Cox proportional haz-
ard models and fractional polynomial regression model,
respectively. As shown in Figure 2, a U-shape dose-
dependent effect was noticed in all cancer patients com-
bined and in patients with individual cancers when ΔHb
was treated as a categorical (Figure 2A) or a continuous
variable (Figure 2B). These data were highly consistent
with that of Table 2, further demonstrating that both sig-
nificantly increased and decreased Hb levels were associ-
ated with adverse survival of cancer patients.
Time-dependent effects of Hb changes on cancer patient
survival
We analyzed the time-dependent effects of |ΔHb| on pa-
tient survival during follow-up after diagnosis, using a
flexible parametric modeling framework adjusting for
host and clinical variables (Figure 3). The increased risk
of death from all cancers conferred by |ΔHb| reached a
peak level at 5.1 months after diagnosis, and remained
significant over 54 months (Figure 3A). Similar effects
were observed for individual cancers (Figures 3B to 3E).
Death risk conferred by anemia modulated by |ΔHb|
The association between anemia and cancer mortality is
influenced by many factors [8]. To evaluate if Hb
changes modulate the predicative role of anemia in can-
cer mortality, we analyzed the association between
anemia, which was indicated by the average Hb level
measured within six months after diagnosis of less than
12 g/dL, and the overall survival of all cancer patients in
this study stratified by different levels of |ΔHb|. In line
with previous reports, Kaplan-Meier curves and log rank
tests indicated that anemic patients had a much shorter
survival (median survival time [MST], 38.2 months)
compared with non-anemic patients (MST, 89.2 months)
(Plog rank=6.2 × 10
-30) (Figure 4A). This difference re-
mained significant in patients with small |ΔHb|. For in-
stance, the MSTs were 140.6 months in non-anemic and
60.2 months in anemic cancer patients with |ΔHb|≤2(Plog rank=2.1 × 10
-13) (Figure 4B). In patients with
|ΔHb| between 2 and 4, the MSTs were 74.3 and 38.9
months in non-anemic and anemic patients, respect-
ively (Plog rank=6.3 × 10
-8) (Figure 4C). However, in pa-
tients with |ΔHb|>4, no significant difference was
observed between non-anemic (MST, 23.1 months) and
anemic (MST, 24.3 months) patients (Plog rank=0.668)
(Figure 4D). The association exhibited similar patterns
after adjusting for all covariates in the main effect analysis
(Additional file 2: Figure S1). Moreover, similar trends
were observed when the analysis was done in individual
cancer sites (Additional file 2: Figure S2). Moreover, the
results remained consistent when the analysis was
conducted by ΔHb instead of |ΔHb| (Additional file 2:
Figure S3). These data indicated that the unfavorable sur-
vival conferred by anemia on cancer patients was modu-
lated by ΔHb after patient diagnosis.
Discussion
In this study, we evaluated the association between ΔHb
measured within six months after cancer diagnosis and
the overall survival of a large population of 6675 patients
of four different solid tumors. Our data indicated that
Hb changes after diagnosis had an adverse effect on the
patient survival. The effect was in a dose-dependent
manner and could persist over a long period after diag-
nosis. In addition, Hb changes seemed to also modulate
the elevated risk of death associated with clinically de-
fined anemia in cancer patients.
Many factors may induce anemia in cancer patients,
such as bleeding, hemolysis, renal insufficiency, insuffi-
cient erythropoiesis caused by chronic inflammatory cy-
tokines during carcinogenesis or myelosuppressive
chemotherapy treatments, and nutrition deficiency
[4,8,22,23]. In the current clinical setting, regardless of
the different underlying causes of anemia, the evaluation
of the severity of anemia mostly depends on the level of
baseline Hb. However, wide variations of Hb levels
among cancer patients, or even the general population,
have been extensively reported, making it difficult to
diagnose anemia solely based on a single measurement
of Hb level at baseline. The newest updated NCCN
guideline suggested that a drop of as little as 2 g/dL in
Hb level, even in non-anemic patients with a high base-
line Hb level, is an alarming indicator for the presence
of anemia [3,24-26]. Nonetheless, as yet there has been
no report systemically evaluating the role of post-
diagnosis change of Hb level in predicting cancer patient
survival. To the best of our knowledge, this is the first
population-based study to assess the association between
Hb change and overall patient survival in multiple can-
cers. Consistent with the suggestions from the NCCN
guideline, our findings indicated that changes in Hb
levels in cancer patients after diagnosis should be
Figure 2 Dose-dependent effects of Hb changes on the survival of cancer patients. (A) Dose-dependent effects of Hb change as a categorical
variable were estimated by Cox proportional hazards model by categorizing Hb changes to −4 (ΔHb<−4), -3 (−4≤ΔHb<−3), -2 (−3≤ΔHb<−2),
-1 (−2≤ΔHb<−1), 1 (1<ΔHb≤2), 2 (2<ΔHb≤3), 3 (3<ΔHb≤4), 4 (ΔHb>4), and 0 (−1≤ΔHb≤1) as reference. Solid spots indicated hazards ratios and the
bars indicated 95% confidence intervals. (B) Dose-dependent effects of Hb change as a continuous variable were analyzed by fractional polynomial
regression model. Solid lines indicated hazard ratios and the shaded areas showed 95% confidence intervals. Both analyses were adjusted for age,
gender, ethnicity, tumor stage, tumor grade, chemotherapy, radiation therapy and surgery. Dash lines represented the references.
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ation and determination of their treatment plans.
We noticed that both decreased and increased Hb
levels were associated with a significantly poorer survival
(Table 2 and Figure 2). The observation for decreased
Hb was not surprising since at least a portion of Hbdecrease might be accounted for by cancer- or
treatment-related anemia. However, it was interesting to
notice that an increase in Hb level, which usually indi-
cates the alleviation of anemia, also conferred an in-
creased risk of death. Moreover, in the analyses for four
cancers combined, as well as individual lung cancer and
Figure 3 Time-dependent effects of Hb changes on the survival
of cancer patients. Flexible parametric modeling framework was used
to assess the effect by Hb changes on the overall survival of patients of
(A) all cancers, (B) lung cancer, (C) breast cancer, (D) colorectal cancer,
and (E) liver cancer. The analysis was adjusted for age, gender,
ethnicity, tumor stage, tumor grade, chemotherapy, radiation therapy
and surgery. Solid lines indicated hazard ratios and shaded areas
showed the 95% confidence intervals. Dash lines represented
the references.
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showed an even more prominent adverse survival com-
pared to those with a decreased Hb, with an HR of 1.53
versus 1.35, 1.59 versus 1.25, and 1.65 versus 1.45, re-
spectively (Table 2). The mechanisms underlying these
observations remain elusive. One potential explanation
might be the use of anti-anemia medications such as
ESAs or PBRC. There have been several recent studies
highlighting the controversial clinical benefits and risks
of using ESAs and/or PBRC to help alleviate cancer- or
therapy-related anemia [9,11,12,27-30]. Some of these
studies reported that overdose or over-duration in the
treatment of anemia might result in elevated rate of pa-
tient death [9-12]. Our results indicated that a signifi-
cant increase in Hb level after cancer diagnosis was
associated with adverse patient survival, substantiating
these previous reports using a population-based epi-
demiological approach. Nonetheless, it should be noted
that although these observations are clinically plausible,
they lack supports from solid clinical evidence since we
currently do not have complete anemia treatment infor-
mation from our chart review-derived database. Future
studies with a more comprehensive collection of anemia
diagnosis and treatment data are warranted to validate
these hypotheses.
Clinically diagnosed anemia has been associated with
unfavorable patient prognosis [31]. However, the current
treatment of anemia does not always result in improved
patient survival, suggesting additional criteria are needed
in determining and monitoring the effects of anti-
anemia therapies [32]. In the present study, we found
that the significantly increased risk of death conferred by
anemia was evident in those patients with a small Hb
change of less than 4 g/dL, but not in those with an Hb
change of more than 4 g/dL (Figure 4). These results in-
dicated that post-diagnosis Hb changes may help im-
prove the decision making process of anemia correction
treatment in clinical settings. Specifically, it raised the
question whether anti-anemia medications should con-
tinuously be administered to patients with a relatively
large change in Hb level in a short period of time. None-
theless, since our analysis did not include anti-anemia
treatments which could significantly confound the results,
independent studies with more complete anti-anemia
Figure 4 Kaplan-Meier curves of the effects of anemia on patient survival by different levels of Hb changes. The analysis was conducted
in (A) all cancer patients, (B) patients with |ΔHb|≤ 2, (C) patients with 2<|ΔHb|≤ 4, and (D) patients with |ΔHb|> 4. Anemia patients were defined
as having an average Hb level<12 g/dL. MST, median survival time.
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regard to their clinical relevance.
Although anemia is a ubiquitous comorbidity in can-
cer patients, its prevalence in different cancer types vary
widely, ranging from 30% to 90% [1]. A recent large
population-based study reported that CRC patients had
the highest incidence of anemia at diagnosis among all
solid tumors, whereas there was no apparent Hb change
in CRC patients within five years before diagnosis [33].
In the present study, post-diagnosis Hb changes in CRC
patients were most significantly associated with overall
survival among the four cancer types, as evidenced by
the 100% validations with P<0.01 in bootstrap re-
sampling in the analyses of both |ΔHb| and ΔHb levels
(Table 2). In comparison, for breast cancer, no significant
results were validated for the association between ΔHb
and patient survival. It remains to be determined as to
whether gender played a role in these observations. We
compared the |ΔHb| of breast cancer patients to that of
female patients of the other three cancers and found that
breast cancer patients had the smallest Hb changes
among all female cancer patients (P<0.001 for all three
comparisons, Figure 1). These differences were likely
due to cancer type instead of gender status, because
such significant differences were not identified be-
tween male and female patients in the other three
cancers (P= 0.056, 0.096 and 0.850 for lung, colorectal
and liver cancers, respectively, Figure 1). Although the
mechanism underlying these cancer type-specific findings
remains to be investigated, these data suggest that the use
of Hb changes in anemia management and patientprognostication should be individually assessed for differ-
ent cancer types.
There are several strengths in this study. We had a
large population of 6675 patients from a single institute
and our conclusions were consistent among four differ-
ent cancer types. The study was focused on the extensive
analysis of a single variable and, thus, did not have the
multiple comparison issue. The findings were highly sta-
tistically significant in both the Cox regression and the
log rank analyses with strict internal validations using
bootstrap resampling, indicating that the possibility of
false positive findings is unlikely. Meanwhile, our study
also has limitations. Because this study used archived
clinical data obtained from chart review instead of pro-
spectively collected data, many cancer type-specific data
did not have complete and/or standardized records in
medical charts and thus had a relatively large percentage
of missing values. In addition, important confounding
variables such as anti-anemia modalities and treatment
toxicities were not complete in our database and thus
not adjusted in the multivariate analyses. Therefore, our
data, although highly statistically significant and bio-
logically plausible, need to be further substantiated in
more rigorous studies using large independent and pro-
spective populations with a more comprehensive collec-
tion of relevant confounding variables.
Conclusions
In summary, our findings suggested that post-diagnosis
Hb changes, regardless of the baseline Hb levels and the
direction of changes, associate with the overall survival
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into consideration in the tailored correction of anemia
treatment. Since cancer- or treatment-related anemia is
present in up to 90% of patients, our finding has consid-
erable significance at the population level. Moreover, be-
cause Hb level is frequently measured in the routinely
tested complete blood count panel, Hb changes may be
a potentially important variable that can be incorporated
with other host and clinical factors to build cancer prog-
nosis assessment models.
Additional files
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